MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.29
-0.56
-2.97%
After Hours: 18.29 0 0.00% 16:00 09/24 EDT
OPEN
18.62
PREV CLOSE
18.85
HIGH
18.98
LOW
17.80
VOLUME
470.52K
TURNOVER
--
52 WEEK HIGH
27.68
52 WEEK LOW
11.75
MARKET CAP
1.36B
P/E (TTM)
-10.3585
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps
Investor's Business Daily · 09/16 17:50
Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
Business Wire · 09/16 12:30
Hedge Funds Have Never Been This Bullish On Dicerna Pharmaceuticals Inc (DRNA)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/10 21:17
Dicerna to Participate in Upcoming September Investor Conferences
Business Wire · 09/02 21:05
Dicerna Pharmaceuticals (DRNA) 2020 Virtual R&D Update - Slideshow
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 08/07 19:22
Dicerna Pharmaceuticals (DRNA) 2020 Virtual R&D Update - Slideshow
Seeking Alpha - Article · 08/07 19:22
Dicerna Pharmaceuticals (DRNA) 2020 Virtual R&D Update - Slideshow
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 08/07 19:22
Dicerna's hepatitis B drug shows encouraging effect in early-stage study
Dicerna Pharmaceuticals (DRNA -6.1%) has shared interim Phase 1 data on its Roche-partnered hepatitis B drug RG6346, demonstrating reduced hepatitis B surf
seekingalpha · 08/06 22:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRNA. Analyze the recent business situations of Dicerna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRNA stock price target is 34.56 with a high estimate of 46.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 236
Institutional Holdings: 71.62M
% Owned: 96.19%
Shares Outstanding: 74.46M
TypeInstitutionsShares
Increased
65
6.11M
New
45
653.85K
Decreased
52
5.72M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
J. Kevin Buchi
President/Chief Executive Officer/Director
Douglas Fambrough
Chief Financial Officer
Douglas Pagan
Chief Operating Officer/Executive Vice President
James Weissman
Executive Vice President/Chief Scientific Officer
Bob Brown
Senior Vice President/Director of Human Resources
Regina Paglia
Vice President
Hardean Achneck
Executive Vice President
Shreeram Aradhye
Vice President
Steven Kates
Other
Robert Ciappenelli
Other
David Caponera
Secretary
Ling Zeng
Other
Rob Ciappenelli
Independent Director
Stephen Doberstein
Independent Director
Martin Freed
Other
Rebecca Peterson
Independent Director
Patrick Gray
Independent Director
Stephen Hoffman
Independent Director
.. ..
Independent Director
Adam Koppel
Independent Director
Marc Kozin
Independent Director
Anna Protopapas
Independent Director
Cynthia Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DRNA
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.